Equity Analysis /

IN : Healthcare - Overall - 4QFY21F result preview

Rahul Agarwal

Analyst @ CGS-CIMB

Shubham Aggarwal

Analyst @ CGS-CIMB

16 April 2021

Published by

CGS-CIMB

Share this article

Base business patient volume recovery would re-confirm FY22-23F estimates. Expect sharp pick-up in antibody testing; EBITDA margins to normalise qoq. Retain Underweight. Lighten positions in the current COVID-19 relapse rally.

Share this article

Most ViewedSee latest

1
Macro Analysis / Global
The 10%-ers: Number of high-yield sovereigns stands at series high
2
Strategy Note / Global
What the banking sector tells us about global investor expectations
3
Strategy Note / Global
The four most profitable listed EM fintechs
4
Strategy Note / Nigeria
Nigeria is top performing equity market, driven by locals not trapped foreigners
5
Strategy Note / Global
Corruption in emerging and developed markets – an ESG investing blindspot

Disclosures:

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.

Full Tellimer disclaimers